The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature
Abstract
Imaging that can detect pathophysiologic change in the brain holds great promise for diagnostic assessment of patients with Alzheimer disease (AD) and dementia. Although a previous metaanalysis centering on literature from 1990 to 2000 showed a summary accuracy of 86% for (18)F-FDG PET for AD diagnosis, the clinical value was considered uncertain because of methodologic shortcomings. Review of the recent literature since 2000 demonstrates that the evidence for (18)F-FDG PET in assessment of dementia has increased with new studies that include autopsy confirmation, wide-diagnostic-spectrum recruitment in primary care settings, historical and prospective cohort studies, and multicenter data analyses. These data support the role of (18)F-FDG PET as an effective and useful adjunct to other diagnostic information in the assessment of patients with symptoms of dementia. Findings are in line with recently revised diagnostic criteria of AD that for the first time recognize the unique role of biomarker evidence in disease definition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“These in vivo imaging findings are consistent with the idea of progressive pathologic spreading in AD from the hippocampal formation to the association cortex (61) and with the Braak and Braak staging model of neurofibrillary tangle pathology in AD (62).”
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationFrontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Qiu, S., Joshi, P. S., Miller, M. I., Xue, C., Zhou, X., Karjadi, C., Chang, G. H., Joshi, A. S., Dwyer, B., Zhu, S., et al. (2020) · Brain · doi:10.1093/brain/awaa137 · Cited by 472
Multimodal deep learning for Alzheimer's disease dementia assessment
Qiu, S., Miller, M. I., Joshi, P. S., Lee, J. C., Xue, C., Ni, Y., Wang, Y., De Anda-Duran, I., Hwang, P. H., Cramer, J. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31037-5 · Cited by 420
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
PET/MRI for Neurologic Applications
Catana, C., Drzezga, A., Heiss, W.-D., & Rosen, B. R. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105346 · Cited by 288
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Brain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236
Aghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bédard, M.-A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.183 · Cited by 220
EFNS task force: the use of neuroimaging in the diagnosis of dementia
Filippi, M., Agosta, F., Barkhof, F., Dubois, B., Fox, N. C., Frisoni, G. B., Jack, C. R., Johannsen, P., Miller, B. L., Nestor, P. J., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03859.x · Cited by 141
Besson, F. L., La Joie, R., Doeuvre, L., Gaubert, M., Mezenge, F., Egret, S., Landeau, B., Barre, L., Abbas, A., Ibazizene, M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0150-15.2015 · Cited by 141
Yoshizawa, H., Gazes, Y., Stern, Y., Miyata, Y., & Uchiyama, S. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2013.10.009 · Cited by 100
Role of imaging in the era of precision medicine
Giardino, A., Gupta, S., Olson, E., Sepulveda, K., Lenchik, L., Ivanidze, J., Rakow-Penner, R., Patel, M. J., Subramaniam, R. M., & Ganeshan, D. (2017) · Academic Radiology · doi:10.1016/j.acra.2016.11.021 · Cited by 87
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria
Caminiti, S. P., Sala, A., Iaccarino, L., Beretta, L., Pilotto, A., Gianolli, L., Iannaccone, S., Magnani, G., Padovani, A., Ferini-Strambi, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0473-4 · Cited by 86
Cavedo, E., Lista, S., Khachaturian, Z., Aisen, P., Amouyel, P., Herholz, K., Jack Jr, C. R., Sperling, R., Cummings, J., Blennow, K., et al. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.32 · Cited by 67
Self-citationBlazhenets, G., Ma, Y., Sörensen, A., Schiller, F., Rücker, G., Eidelberg, D., Frings, L., & Meyer, P. T. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230797 · Cited by 58
“Aside from lower costs and wider availability, an additional strength of 18FFDG PET over amyloid PET may be the detection of neurodegenerative causes of MCI that are not associated with brain amyloidosis (20,21).”
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Hellwig, S., Frings, L., Bormann, T., Vach, W., Buchert, R., & Meyer, P. T. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4111-3 · Cited by 32
Dall'Angelo, S., Bandaranayaka, N., Windhorst, A. D., Vugts, D. J., van der Born, D., Onega, M., Schweiger, L. F., Zanda, M., & O'Hagan, D. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.02.006 · Cited by 31
Soucy, J.-P., Bartha, R., Bocti, C., Borrie, M., Burhan, A. M., Laforce, R., & Rosa-Neto, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt199 · Cited by 25
PET Imaging of Epigenetic Influences on Alzheimer’s Disease
Couto, P. J., & Millis, R. M. (2015) · International Journal of Alzheimer's Disease · doi:10.1155/2015/575078 · Cited by 19
Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes
Bergeron, D., Beauregard, J.-M., Guimond, J., Fortin, M.-P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., & Laforce, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150302 · Cited by 17
“Moreover, we should emphasize that the goal of the study was not to assess FDG-PET accuracy, which has already been studied (see [7] for a review), but rather evaluating its clinical impact in real-life practice.”
Metadata
- Authors
- Bohnen, N. I., Djang, D. S. W., Herholz, K., Anzai, Y., & Minoshima, S.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2011-12-15
- Volume
- 53
- Issue
- 1
- Pages
- 59-71
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2132680220
- Cited by
- 286
- References
- 96
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.